



www.genfit.com

GENFIT FINALIZES A €9.6 M REAL ESTATE TRANSACTION IN ITS FAVOR

- This increase in corporate resources is non-dilutive for its shareholders.
- The cost of use of the premises remains unchanged.

Lille (France), Boston (Massachusetts, United States), March 22, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the sale of its laboratories and offices situated in the Eurasanté business park, to an investor specialized in healthcare real estate.

At the end of 2012, GENFIT became the owner of its premises by exercising the early purchase option of its leasing-purchase agreement. Given their potentially substantial value, GENFIT decided to sell its premises to an investor in a transaction that generates, after VAT, a net cash sum for GENFIT of approximately €8 M. By becoming the tenant of this investor, GENFIT will pay rent that is similar to the annual charges of the previous leasing-purchase agreement, at approximately €900 K per year. GENFIT remains the sole occupant of the offices, laboratories, and grounds that make up this prestigious real estate complex at the entrance to the Eurasanté business park. Following the transaction, the Company's cash balance amounts to €16.3 M.

Jean-François Mouney, Chairman and CEO of GENFIT, stated: *«The core business of GENFIT being pharmaceutical research and development, we wish to dedicate all our available resources to this activity in order to continue to strengthen the value of our product portfolio. The completion of this real estate sale brings us significant additional resources that are non-dilutive for our shareholders. We intend to continue to strengthen our funding while moderating the impact of the operations for our existing shareholders.»*

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr